Negative effect of fatty liver on visualization of pancreatic cystic lesions at screening transabdominal ultrasonography
Negative effect of fatty liver on visualization of pancreatic cystic lesions at screening transabdominal ultrasonography
复制标题
脂肪肝对经腹超声筛查时胰腺囊性病变可视化的负面影响
DOI：
10.1111/jep.13138
复制
发表时间：
2019
影响因子：
2.4
通讯作者：
Kanai Takanori
中科院分区：
文献类型：
--
作者：
Kashiwagi Kazuhiro;Seino Takashi;Makino Kanako;Shimizu‐Hirota Ryoko;Takayama Michiyo;Yoshida Toshifumi;Iwasaki Eisuke;Sugino Yoshinori;Inoue Nagamu;Iwao Yasushi;Kanai Takanori
基本原理、目的和目标 这项观察性研究的目的是，以磁共振成像 (MRI) 作为参考标准，确定一些胰腺囊性病变 (PCL) 在经腹超声检查 (TAUS) 中无法检测到的因素。 方法 数据库包含 781 名连续接受健康检查（包括脂肪计算机断层扫描和上腹部 MRI）的受试者。 搜索过。通过 TAUS 诊断脂肪肝和脂肪胰腺的存在，并通过重新评估胸部计算机断层扫描中的胰腺图像进行筛查来确定萎缩性胰腺。对 TAUS 检测到 PCL 的受试者和未检测到 PCL 的受试者的临床特征进行统计比较。结果 MRI 检测到的 PCL 在一般人群中的患病率为 17.8%。多变量logistic回归分析显示，脂肪肝、体重指数和PCL大小与影响TAUS时PCL可视化的因素显着相关（比值比[OR]：0.337，95%置信区间[CI]：0.154-0.734，P=0.006；OR：0.852，95% CI： 0.737‐0.985，P=0.030； OR：1.120，95% CI：1.045‐1.200，P=.001）。 TAUS 低估了总共 56 个 PCL 中的 36 个 PCL (64.3%)。此外，16 个 PCL（≥ 15 mm）中的 9 个（≥ 15 mm）通过 TAUS 测量不足 5 mm 或更多，尽管 PCL（≥ 15 mm）的检出率明显高于 PCL（< 15 mm）（80% vs 33.6%，P=.000）。结论应该指出的是，共存脂肪肝可能会降低聚己内酯, TAUS 可能会低估其大小。
Rationale, aims, and objectivesThe aim of this observational study is to identify factors by which some pancreatic cystic lesions (PCLs) were undetectable at transabdominal ultrasonography (TAUS), using magnetic resonance imaging (MRI) as reference standard.MethodsThe database for 781 consecutive subjects who underwent a health checkup including fat computed tomography and upper abdominal MRI as option was searched. The presence of fatty liver and fatty pancreas was diagnosed by TAUS, and atrophic pancreas was determined by reevaluating the image of the pancreas in the chest computed tomography for screening. Subjects with PCL detected and those undetected at TAUS were statistically compared in clinical characteristics.ResultsThe prevalence of PCL detected at MRI was 17.8% in the general population. Multivariate logistic regression analysis showed that fatty liver, body mass index, and the size of PCL were significantly associated with the factors influencing the visualization of PCL at TAUS (odds ratio [OR]: 0.337, 95% confidence interval [CI]: 0.154‐0.734,P= 0.006; OR: 0.852, 95% CI: 0.737‐0.985,P= 0.030; OR:1.120, 95% CI: 1.045‐1.200,P= .001). Thirty‐six PCLs (64.3%) in a total of 56 PCLs were undermeasured by TAUS. Additionally, nine (56%) out of 16 PCLs (≥ 15 mm) were undermeasured by 5 mm or more by TAUS, although a significantly higher detection rate was observed for PCLs (≥ 15 mm) in comparison with that for PCLs (< 15 mm) (80% vs 33.6%,P= .000).ConclusionsIt should be noted that coexisting fatty liver may lower the detection of PCL, and its size may be underestimated by TAUS.